QIMING U.S. VENTURES MANAGEMENT, LLC
Follow13F filer, CIK 1909617, BELLEVUE, WA
QIMING U.S. VENTURES MANAGEMENT, LLC reported $51,364,552 across 6 holdings for the quarter ended 2024-09-30, in a 13F-HR filed 2024-11-07.
Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001104659-24-115326
- Period
- 2024-09-30
- Reported value
- $51.4M
- Holdings
- 6
- Top 10 weight
- 100%
- New
- 0
- Sold out
- 0
Holdings, Q3 2024
Share positions as resolved from 13F-HR 0001104659-24-115326, largest first. % of portfolio is the value over $51,364,552, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| Tourmaline Bio IncTourmaline Bio Inc | 741,691 | $19.1M | 37.12% | 0 | |||
| JSPRJASPER THERAPEUTICS INC | 928,964 | $17.5M | 34.02% | 0 | Timeline | ||
| KRROKORRO BIO INC | 368,085 | $12.3M | 23.95% | 0 | Timeline | ||
| HILLEVAX INCHILLEVAX INC | 558,923 | $984K | 1.92% | 0 | |||
| VTYXVENTYX BIOSCIENCES INC | 412,225 | $899K | 1.75% | 0 | Timeline | ||
| KEZAR LIFE SCIENCES INCKEZAR LIFE SCIENCES INC | 828,711 | $638K | 1.24% | 0 |
How Q3 2024 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0001104659-24-115326 | base | 2024-11-07 | acceptance time not in the bulk data set |